Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Idorsia Ltd
  6. News
  7. Summary
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Idorsia : Daridorexant Shows Sleep Improvement in Insomnia Patients

06/09/2021 | 01:36am EDT


ę MT Newswires 2021
All news about IDORSIA LTD
07/29IDORSIA : Application of Jean-Paul and Martine Clozel regarding the exemption fr..
PU
07/29PRESS RELEASE : Application of Jean-Paul and -2-
DJ
07/29PRESS RELEASE : Application of Jean-Paul and Martine Clozel regarding the exempt..
DJ
07/28IDORSIA : Places $660 Million Convertible Bonds Due 2028; Shares Down 10%
MT
07/28IDORSIA : announces the reference share price and the initial conversion price o..
AQ
07/28PRESS RELEASE : Idorsia announces the reference -2-
DJ
07/28PRESS RELEASE : Idorsia announces the reference share price and the initial conv..
DJ
07/28IDORSIA : successfully completes the offering of convertible bonds, securing fun..
PU
07/28PRESS RELEASE : Idorsia successfully completes the -2-
DJ
07/28PRESS RELEASE : Idorsia successfully completes the offering of convertible bonds..
DJ
More news
Financials
Sales 2021 32,1 M 35,4 M 35,4 M
Net income 2021 -638 M -703 M -703 M
Net Debt 2021 378 M 416 M 416 M
P/E ratio 2021 -5,73x
Yield 2021 -
Capitalization 3 734 M 4 123 M 4 115 M
EV / Sales 2021 128x
EV / Sales 2022 48,2x
Nbr of Employees 650
Free-Float 63,4%
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 22,32 CHF
Average target price 30,80 CHF
Spread / Average Target 38,0%
EPS Revisions
Managers and Directors
Jean-Paul Clozel Chief Executive Officer & Director
AndrÚ C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
IDORSIA LTD-13.40%4 046
GILEAD SCIENCES, INC.20.25%87 868
BIONTECH SE283.45%75 705
WUXI APPTEC CO., LTD.38.94%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-15.22%52 353